By K. Giacomo. Southampton College.
Two studies looked at the number of patients with exacerbations and2 found no significant differences between treatments purchase nolvadex with mastercard. There was also little difference in adverse effects between the 2 treatments cheap 20 mg nolvadex with mastercard. In a good- quality trial of adults (89% African American) presenting to an emergency department with 84 acute asthma order nolvadex from india, Salo and colleagues randomized 66 patients to either albuterol 7 discount nolvadex 20mg with mastercard. There was no significant difference in hospital admission rates between the combination therapy (25%) and albuterol monotherapy groups (16. The odds ratio for hospital admissions in the combination group was 1. Quick-relief medications for asthma Page 20 of 113 Final Report Update 1 Drug Effectiveness Review Project Pediatric asthma 9 The Cochrane review by McDonald and colleagues included studies of children using an anticholinergic drug for more than 1 week. One very small trial compared ipratropium bromide plus salbutamol with placebo plus salbutamol, both delivered by metered aerosol 4 times daily. A second trial compared ipratropium bromide plus fenoterol with placebo plus fenoterol delivered via nebulizer 3 times daily. Both trials failed to show any significant benefit with respect to symptom scores from the addition of anticholinergic drugs to beta -agonist monotherapy. In a fair-quality trial set in India, children age 5 to 15 years with mild to moderate acute exacerbation of asthma were randomized to either 4 actuations of ipratropium bromide (80 µg total) or placebo given with a metered dose inhaler using a spacer. All children were first given 4 actuations of salbutamol (400 mcg total) via a metered dose inhaler and spacer, then the study drug. Thirty minutes after treatment there was no significant difference between treatments in scores for wheezing or for use of accessory muscles. For both therapies, 3 doses were delivered by nebulizer at 20-minute intervals. Oral corticosteroids were administered to all children, and additional doses of salbutamol were administered for incomplete response. Follow-up by mail showed that the groups had similar rates of a close secondary attack that required rescue medication (9% with combination therapy and 21% with monotherapy). Data were available for 85% of randomized subjects, and close was not defined. Subgroup analyses based on age and severity showed no statistically significant differences between the 2 groups at any time, but it was unclear which outcomes were examined for these analyses. Both therapies were delivered by nebulization every 20 minutes for 3 doses. Oxygen was administered; there was no mention of corticosteroids. Dyspnea, wheeze, and accessory muscle scores decreased from baseline more with combination therapy than with monotherapy (between-group P<0. Hospitalization occurred in 1 patient in the combination therapy group and 4 subjects in monotherapy. Ipratropium bromide compared with ipratropium bromide plus albuterol Adult asthma 103 In a small, fair- to poor-quality trial in New Zealand, 36 adults with mild to moderate asthma using inhaled corticosteroids were randomized to 4 puffs three times daily of salbutamol 100 ® µg/ipratropium bromide 20 µg daily via a metered dose inhaler (Combivent ) or ipratropium ® bromide 20 µg 4 puffs 3 times daily (Atrovent ). Both groups used ipratropium bromide 40 Quick-relief medications for asthma Page 21 of 113 Final Report Update 1 Drug Effectiveness Review Project µg/puff for symptom relief. After 2 weeks of the assigned treatment drug (Phase 1), the inhaled steroids were withdrawn from both groups (Phase 2). Patients were then observed until one of the following predetermined criteria for loss of control of asthma were met: mean morning peak expiratory flow rates <90%, mean run-in values in 2 consecutive morning peak flow rates <80% of mean values during the run-in period; night wakening occurring 2 or more nights per week more often than during run-in; or distressing or intolerable symptoms. The mean time to loss of control was shorter in the salbutamol/ipratropium bromide group (8. Because at baseline the 2 treatment groups differed nonsignificantly (at alpha=0. This post hoc analysis of subjects matched by FEV (% predicted) showed no significant difference in days to loss of control (1 P>0. The systematic review of chronic ipratropium bromide use in adults by Westby and 12 colleagues did not discuss this comparison explicitly, although this comparison was compatible with their inclusion criteria. It is unclear if they did not identify studies comparing ipratropium bromide plus albuterol with ipratropium bromide, or if they did not include this comparison. Pediatric asthma We identified no studies comparing the effect of ipratropium bromide with and without albuterol on control of asthma in children. Albuterol compared with pirbuterol Demographic and study characteristics are summarized in Table 7. Of the 3 studies (in 4 publications) that provided direct comparative data on these 14, 15, 67, 68 14, 15 67 drugs, 2 were of poor quality, and 1 was of fair quality. None of these studies provided data on effectiveness outcomes. Albuterol compared with fenoterol: Comparisons relevant to Canada Only 1 of the 24 head-to-head studies identified comparing albuterol with fenoterol reported 21 effectiveness outcomes for asthma. Albuterol compared with terbutaline: Comparisons relevant to Canada Adult asthma Demographic and study characteristics are summarized in Table 10 and effectiveness outcomes in Table 11. Use of rescue medications was examined and found to be similar in 2 poor-quality trials. In an adult asthma population 19 Gioulekas and others did not find a significant difference in use of rescue medication. In adults with asthma, symptom scores did not differ between albuterol and terbutaline in 13, 19, 22 3 studies (2 poor- and 1 fair-quality). In a fourth (poor-quality) randomized controlled trial 80 of 159 adults with asthma, the mean daytime asthma symptom score (P<0. Quick-relief medications for asthma Page 22 of 113 Final Report Update 1 Drug Effectiveness Review Project Pediatric asthma In pediatric asthma there was no significant difference in symptoms between the 2 70, 77, 79 77 drugs and respiratory rate decreased after both treatments. In exercise-induced asthma in a pediatric population, the only effectiveness outcome reported was the need for aminophylline treatment. Fenoterol compared with terbutaline: Comparisons relevant to Canada Adult asthma Demographic and study characteristics are summarized in Table 12. There was no difference in patient 97 preference between the 2 drugs in another study. Fenoterol compared with ipratropium bromide: Comparisons relevant to Canada Adult asthma There were no data in adults. Pediatric asthma 9 The Cochrane review by McDonald and colleagues included a study comparing fenoterol 0. After more than 1 week no significant difference in symptom scores was seen in children with mild stable 104 asthma. We did not identify any additional studies for this comparison. Fenoterol plus ipratropium bromide compared with fenoterol: Comparisons relevant to Canada Adult asthma There were no data in adults. Pediatric asthma 9 The Cochrane review by McDonald and colleagues included 1 small trial that compared 105 fenoterol plus ipratropium bromide with fenoterol monotherapy. However, McDonald and colleagues did not identify sufficient data in the primary study to draw conclusions on comparative effectiveness. Pirbuterol compared with terbutaline: Comparisons relevant to Canada We identified no studies comparing pirbuterol with terbutaline in asthma. Quick-relief medications for asthma Page 23 of 113 Final Report Update 1 Drug Effectiveness Review Project Safety Key Question 2. What are the comparative incidence and severity of adverse events reported from using quick-relief medications to treat outpatients with bronchospasm due to asthma or to prevent or treat exercise-induced bronchospasm? Overview of adverse events Withdrawal rates are presented in Table 14. Adverse events related to sympathomimetic side effects are expected with these medications and are discussed below. There was also a broad range of gastrointestinal, musculoskeletal, and other miscellaneous adverse events. There were no apparent differences in the rates and severity of adverse events between the various drugs compared in this review. Albuterol compared with levalbuterol Adult asthma Total withdrawal rates in studies comparing albuterol with levalbuterol ranged from 0% to 54 11. Withdrawal rates were similar between the 2 drugs with neither drug consistently reporting higher rates.
The Comparative Efficacy and Safety of Carbamazepine Versus Lithium: A Randomized purchase genuine nolvadex on line, Double-Blind 3-Year Thai in 83 Patients buy generic nolvadex 10 mg on line. Watkins SE buy nolvadex 10mg fast delivery, Callender K purchase nolvadex 10mg free shipping, Thomas DR, Tidmarsh SF, Shaw DM. The Effect of Carbamazepine and Lithium on Remission from Affective Illness. Lithium versus carbamazepine in the maintenance treatment of bipolar II disorder and bipolar disorder not otherwise specified. The comparative prophylactic efficacy of lithium and carbamazepine in patients with bipolar I disorder. Greil W, Kleindienst N, Erazo N, Muller-Oerlinghausen B. Differential response to lithium and carbamazepine in the prophylaxis of bipolar disorder. Journal of Clinical Psychopharmacology Vol 18(6) Dec 1998, 455-460. Lithium versus carbamazepine in the maintenance treatment of bipolar disorders--a randomised study. Inter-episodic morbidity and drop-out under carbamazepine and lithium in the maintenance treatment of bipolar disorder. Antiepileptic drugs Page 60 of 117 Final Report Update 2 Drug Effectiveness Review Project 79. A preliminary double-blind study on the efficacy of carbamazepine in prophylaxis of manic-depressive illness. Lithium vs cambamazepine in the maintenance treatment of schizoaffective disorder: A randomised study. European Archives of Psychiatry and Clinical Neuroscience 1997;247(1):42-50. Prophylactic effect of phenytoin in bipolar disorder: a controlled study. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. A double-blind, randomized, placebo-controlled, prophylaxis study of adjunctive gabapentin for bipolar disorder. Long-term randomized clinical trial on oxcarbazepine vs lithium in bipolar and schizoaffective disorders: Preliminary results. Case studies on prophylactic long-term effects of Oxcarbazepine in recurrent affective disorders. International clinical Psychopharmacology 1990;5 (suppl 1):89-94. Calabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan E, Rudd GD. A double- blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamotrigine in the acute treatment of bipolar depression: Results of five double-blind, placebo-controlled clinical trials. A Multicenter, Double-Blind, Placebo- Controlled, Fixed-Dose, 8-Week Evaluation of the Efficacy and Safety of Lamotrigine in the Treatment of Bipolar Disorder Patients Currently Experiencing a Major Depressive Episode. A Multicenter, Double-Blind, Placebo- Controlled, Fixed-Dose Evaluation of the Safety, Efficacy, and Tolerability of LAMICTAL (Lamotrigine) in the Treatment of a Major Depressive Episode in Patients with Type I Bipolar Disorder. A Multicenter, Double-Blind, Placebo- Controlled, Fixed-Dose, 8-Week Evaluation of the Efficacy and Safety of Lamotrigine in the Treatment of Major Depression in Patients with Type II Bipolar Disorder. A Multicenter, Double–Blind, Placebo– Controlled, Flexible Dose (100–400mg) 10 Week Evaluation Of the Safety and Efficacy of LAMICTAL (Lamotrigine) in the Treatment of a Major Depressive Episode in Patients with Bipolar Disorder. A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. Antiepileptic drugs Page 61 of 117 Final Report Update 2 Drug Effectiveness Review Project 93. Randomized, double-blind pilot trial comparing lamotrigine versus citalopram for the treatment of bipolar depression. A single blind comparison of lithium and lamotrigine for the treatment of bipolar II depression. Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. Clinical predictors of response to lamotrigine and gabapentin monotherapy in refractory affective disorders. Divalproex in the treatment of bipolar depression: a placebo-controlled study. Divalproex in the treatment of acute bipolar depression: a preliminary double-blind, randomized, placebo-controlled pilot study. Practice guidelines for the treatment of patients with bipolar disorder: Second Edition. McIntyre RS, Mancini DA, McCann S, Srinivasan J, Sagman D, Kennedy SH. Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminary single-blind study. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. A double-blind placebo-controlled study of lamotrigine in rapid cycling bipolar disorder. Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. A 14-week, Randomized, Double-Blinded, Placebo-Controlled Monotherapy Trial of Pregabalin in Patients With Fibromyalgia. A randomized double blind placebo controlled phase III trial of pregabalin in the treatment of patients with fibromyalgia. Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): A 6-month, double-blind, placebo- controlled trial with pregabalin Pain. Antiepileptic drugs Page 62 of 117 Final Report Update 2 Drug Effectiveness Review Project 109. Millan-Guerrero RO, Isais-Millan R, Barreto-Vizcaino S, et al. Subcutaneous histamine versus sodium valproate in migraine prophylaxis: a randomized, controlled, double-blind study. A comparative trial of prinodolol, clonidine and carbamazepine in the interval therapy of migraine. Efficacy of topiramate and valproate in chronic migraine. Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo- controlled trial. Low-dose topiramate versus lamotrigine in migraine prophylaxis (the Lotolamp study). Topiramate and triptans revert chronic migraine with medication overuse to episodic migraine. Efficacy and tolerability of topiramate 200 mg/d in the prevention of migraine with/without aura in adults: a randomized, placebo- controlled, double-blind, 12-week pilot study. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Silvestrini M, Bartolini M, Coccia M, Baruffaldi R, Taffi R, Provinciali L. Oxcarbazepine in migraine headache: a double-blind, randomized, placebo-controlled study. Shaygannejad V, Janghorbani M, Ghorbani A, Ashtary F, Zakizade N, Nasr V.
As soon as you find yourself in a group of at least three people order 20 mg nolvadex free shipping, the odds are that you will listen rather than speak order nolvadex 20mg with amex. The bigger the group purchase nolvadex mastercard, the smaller your contribution buy discount nolvadex 10 mg line. In some situations – at school, university, or during meetings at work – you could listen for hours, and nobody would expect you to contribute more than a word or two. As a result of years of listening, the part of your word brain that processes sounds is better trained than the part that produces speech. The words put into your brain are more diverse than the words coming out of it. You have only one life to tell – your own – while your co-humans make you listen to hundreds of different lives in different places and in different circumstances. You know words annunciated by fascists, fundamentalists and populists that you wouldn’t want to ever pass your lips. You know hundreds or thousands of words from listening to priests, rabbis, and imams, but, again, you would not want to use them yourself because, as a scientist, you feel that God and the gods exist because our ancestors had the wisdom to create them. This list can go on and on, including Print: Amazon. Because of the huge variability of human biographies – sometimes disgustingly ugly, but most often creative, stimulating, and refreshing – you know thousands of words you will never utter. What you know of the world is more than what you can say about it. Imagine living the life of a distant ancestor 100,000 years ago. How would you value listening skills with respect to speaking skills? What could be more useful for survival, the correct interpretation of the sounds around you – ‘Is that a wolf? But this discussion is beyond the frame of a short language guide. I promised you that you would partly avoid producing stuttering and ungraceful speech. If you are abroad, every day presents hundreds of opportunities to speak to friends and strangers. If, instead, you are at home, listen to your favourite language CDs and repeat the now familiar words and sentences. Imitate the sounds, in particular the length of the vowels and the melody of the sentences. Later, repeat the sentences in real-time, with an interval of just one second. You will be amazed at how the sounds soon start to come out of your mouth. Repeating the lessons of your language manuals will take you some weeks. Again, don’t feel uncomfortable repeating a th language CD for the 14 time. Thereafter, use the same procedure – listening to and reproducing speech with a one- second interval – with sentences from other sources such as podcasts, audio books, or TV. In the beginning, real-life speech Web: TheWordBrain. Have you noticed that I have again limited free expression? I suggested that you repeat the sentences of language manuals, TV, and audio books. In other words, I recommended that you do not translate from your native language. Translations are risky for a language novice because they generate a large number of errors. You might get accustomed to these errors and end up being unable to say what is right and what is wrong. Whenever possible, it is thus preferable that you use words and sentences that you have already heard being said by other people. At this early stage, don’t be ashamed to be a parrot. While transmuting into a parrot is generally feasible, another fundamental conversion may be out of reach for some individuals. Imagine that you step into one of the Paris boulevard restaurants and order an overprized micro-bottle of mineral water and a dish of spaghetti bolognese. The art of al-dente cooking hasn’t arrived in France yet. To be honest, you didn’t look like a weathered adult, in control of life, family and career, but rather like a clumsy and gawky creature or bungling adolescent, struggling to find your way in the world. That’s the way it is: during your first steps in a new language, at best, you regress to a kind of cutesy childhood, at worst, you are a weirdo, a nobody, an untouchable. Some people perceive this as a high price for familiarising themselves with other languages and decide that they are not willing to pay the price. They don’t want, at any cost, to look clumsy, awkward, or inept. That is, of course, the end of the dream of speaking another language. Without going through the baby/stranger/klutzy stage, nobody will ever learn to speak another language. All of a sudden, we realise that discipline, dedication and perseverance alone are not enough. To pierce the walls of other languages, you need more extensive qualities. We begin to understand that the true reasons for ‘not having talent for foreign languages’ may not be related to memory or grammar or laziness, but might well be psychological in nature. I assume that you are willing to pay the price, so that your speaking skills will gradually improve and accelerate. You will notice that over the years (yes, we are now talking about years and not about weeks or months), speech production will become increasingly unconscious. Even your foreign accent will eventually soften, although probably never disappear. If you choose the right words and fold them in perfect grammar, nobody will ever dare blame you. As in other areas, content is more important than packaging. As long as you speak fluently, an accent is not debilitating, on the contrary. In today’s world, especially in times of peace, some accents are truly charming. To go through the process of language acquisition, you will 1. Knowing the operating mode of a machine can be helpful before turning it on. And another question surely springs to mind: Is there some sort of talent involved in language learning? Before summarizing the learning strategies for the monumental task of absorbing thousands of words, let’s dig into your memory. Workload after Chapter 1–5 Due to heavy exposure to human speech during your CD and/or TV training (see Chapter 2), once you start speaking, progress will be fast. For your initial training sessions, we generously allocate 50 extra hours. Your total workload is now 850 to 1,850 hours Print: Amazon. That is in stark contrast to what you will experience with subsequent languages where initially nothing ever happens in milliseconds. Imagine that, during your first trip to Paris, a friendly local takes you on a two-hour stroll from Notre Dame to the Louvre, then northwards up to the Sacré- Cœur, and, finally, down to Pigalle. If I put you back at Notre Dame a few months later, you would probably find your way to Pigalle alone, recalling places, streets, crossroads, shops, and buildings. It is hard to believe that this wealth of information is approximately equivalent to learning 20 miserable words.
Similar improvements were seen in Global Assessment of Function (GAF) and cognitive scores cheap nolvadex american express. Escitalopram compared with fluoxetine One 8-week study compared escitalopram nolvadex 10 mg with mastercard, fluoxetine order nolvadex 10 mg fast delivery, and placebo in 518 participants older than 65 65 years of age (mean age in each treatment group cheap 20 mg nolvadex fast delivery, 75 years). Patients on escitalopram experienced greater improvement than those on fluoxetine in MADRS score (using LOCF analysis) at week 8 (P < 0. Escitalopram, placebo, and fluoxetine MADRS response rates were similar (46%, 47%, and 37%, respectively, P=not significant). In addition, MADRS remission rates were similar for escitalopram and placebo (40% and 42%), but for fluoxetine compared with placebo, the difference was statistically significant (30% compared with 42%, P=0. Escitalopram- and fluoxetine-treated patients experienced significantly more nausea than placebo-treated patients (P < 0. Fluoxetine compared with paroxetine 68, 71 Two RCTs were conducted in a population older than 60 years. The first trial was an Italian study lasting 1 year that enrolled 242 patients to determine the effects of fluoxetine (20-60 mg/d) and paroxetine (20-40 mg/d) on mood and cognitive function in depressed, non-demented persons (65 years or older). Both groups significantly improved on their HAM-D scores and cognitive performance. Paroxetine showed a faster onset of action and a significantly greater Second-generation antidepressants 90 of 190 Final Update 5 Report Drug Effectiveness Review Project improvement of HAM-D scores during the first 6 weeks (Week 3: P<0. A Kaplan-Meier analysis evaluating the percentage of responders over time revealed a significant difference in favor of paroxetine (P<0. Treatment groups did not differ significantly in CGI scores. Fluoxetine had a significantly greater number of patients with severe adverse events than paroxetine (22 compared with 9; P<0. The second trial conducted in an elderly population enrolled 108 patients with major 71 depression in Austria and Germany for 6 weeks using the same dosage as the Italian study. An intention-to-treat analysis revealed no differences between the treatment groups in changes of scores on MADRS and HAM-D; the paroxetine group had significantly more responders at 6 weeks on MADRS and HAM-D scales (37. Patients on paroxetine also had significantly better MMSE and SCAG scores assessing cognitive function at Week 3 than did those on fluoxetine. No statistically significant differences in adverse events were reported. Fluoxetine compared with sertraline One fair, 12-week study comparing fluoxetine to sertraline was conducted in 236 participants 77, 79 older than 60 years. In this study, outcome measures also included quality of life (Q-LES-Q) and cognitive assessments (SLT, MMSE, Digital Symbol Substitution Test). Fluoxetine- and sertraline-treated patients did not differ significantly on primary outcome measures (MADRS, HAM-D). Response rates (fluoxetine, 71%; sertraline, 73%) and remission rates (46% compared with 45%) were similar. Quality of life and other patient-rated secondary efficacy measures were similar for both treatment groups at endpoint. Sertraline-treated patients showed a greater cognitive improvement on the Digit Symbol Substitution Test at endpoint (P=0. A subgroup analysis of 75 patients 70 years of age or 79 older showed a greater response rate for sertraline-treated patients (P = 0. A subgroup analysis of a long-term effectiveness trial comparing fluoxetine, paroxetine, and sertraline reports similar response and remission rates for patients older than 65 years and 55 the general study population. Mirtazapine compared with paroxetine 89 A fair trial randomized 255 elderly participants for eight weeks. Mirtazapine and paroxetine were equally effective in reducing HAM-D scores at the endpoint, but mirtazapine lead to a faster response. A Kaplan-Meier analysis showed a significantly faster time to response for mirtazapine (mean 26 days compared with mean 40 days for paroxetine; P=0. No significant difference in response rates on the CGI scale was noted. Significantly more mirtazapine-treated patients reported weight gain (P<0. Paroxetine- treated patients reported a significantly higher rate of nausea, tremor, and flatulence (P<0. Venlafaxine compared with citalopram A fair European 6-month study compared venlafaxine ER (37. No statistical differences in any outcome measures (MADRS< CGI-S, CGI-I) could be detected at study endpoint. The remission rates were 19 percent for venlafaxine and 23 percent for citalopram. Both treatment groups reached a 93 percent response rate. Second-generation antidepressants 91 of 190 Final Update 5 Report Drug Effectiveness Review Project Venlafaxine compared with fluoxetine One fair trial compared venlafaxine IR (37. Both treatment groups experienced a significant reduction in HAM-D total scores at 8 weeks; however, there were no significant differences between groups in HAM-D, MADRS, or CGI scores at endpoint. Remission rates at 8 weeks were 27 percent for venlafaxine and 20 percent for fluoxetine. Venlafaxine-treated patients experienced significantly higher rates of nausea (45% compared with 23%), dry mouth (23% compared with 6%) and constipation (22% compared with 10%); P<0. Venlafaxine compared with sertraline One study determined efficacy and safety of venlafaxine (25-100 mg/d) compared to sertraline 293 (18. We graded the quality of this study as poor for efficacy because of high loss to follow-up (44. The investigators reported a significantly higher rate of withdrawal among venlafaxine- than sertraline-treated patients (63% compared with 24%). In addition, venlafaxine-treated patients had a significantly higher rate of severe adverse events (P=0. Venlafaxine compared with SSRIs A pooled data analysis combined original data from eight comparable, double-blind, active- 294, 295 controlled, randomized trials. A primary objective of this analysis was to determine differences in response and remission based on sex and age. This study was not based on a systematic literature search, so results must be viewed cautiously. For venlafaxine-treated 295 patients, neither age (< 50 or > 50 years of age) nor sex affected remission rates. Among patients treated with SSRIs, however, a significant interaction was observed between treatment and sex (P=0. Remission rates for older women treated with venlafaxine (48%) were higher than remission rates for older women treated with SSRIs (28%, P=0. Hormone replacement therapy appeared to eliminate these differences. Additional analyses of age subgroups (< 40, 41- 54, 55-64, and > 65 years of age) and sex subgroups revealed that no significant age-by- treatment, sex-by-treatment, or age-by-sex-by-treatment interactions occurred. Men and women of different ages within each treatment group had similar rates of remission, response, and 294 absence of depressed mood. Among patients over 40 years of age, the rates of adverse events were similar between the treatment groups, although venlafaxine-treated patients aged 55 to 64 years reported significantly more nausea than placebo (P<0. Bupropion compared with paroxetine One fair RCT examined the efficacy of bupropion SR (100-300 mg/d) and paroxetine (10-40 111, 112 mg/d) in 100 outpatients ages 60 years or older (range 60-88 years) over 6 weeks. The majority of patients were white (bupropion SR, 98%; paroxetine, 90%), female (bupropion SR, Second-generation antidepressants 92 of 190 Final Update 5 Report Drug Effectiveness Review Project 54%; paroxetine, 60%), and did not use antidepressants for the current episode before enrollment (bupropion SR, 83%; paroxetine, 88%). The overall loss to follow-up was 16 percent with no significant difference between treatment groups. Efficacy according to any outcome measure did not differ significantly between treatment groups. Response rates (≥ 50% reduction in HAM-D scores) were similar in both groups (bupropion SR, 71%; paroxetine, 77%). Quality-of-life scales (QLDS, SF-36) showed statistically significant improvements in both treatment groups from baseline to endpoint (P<0. Ethnicity No studies directly compared the efficacy, effectiveness and harms of second-generation antidepressants among different races or ethnicities.